Phase II study of low-dose topotecan in myelodysplastic syndromes: A Hoosier Oncology Group (HOG) study

Daniel A. Vaena, Paul Walker, Kenneth Pennington, Anthony Stephens, Michael J. Stender, Constantin T. Yiannoutsos, Carol Young, Cindy Stoner, Larry D. Cripe

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2mg/m 2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied topotecan 1.5mg/m2 per day i.v. over 2h for three consecutive days in 20 patients with high-risk MDS (12 RAEB; 4 RAEB-T; 4 CMMoL). Cycles were given every 4-6 weeks. Fifteen patients were evaluable for response. Only one patient achieved a durable complete remission (CR). There were three deaths within the first cycle of therapy. Severe myelosupression was the most common toxicity. Grades 3-4 infections were documented in four patients. We conclude that topotecan administered at this dose and schedule has no clinically significant activity.

Original languageEnglish (US)
Pages (from-to)49-52
Number of pages4
JournalLeukemia Research
Volume28
Issue number1
DOIs
StatePublished - Jan 2004

Keywords

  • Acute myeloid leukemia
  • Induction
  • Low-dose chemotherapy
  • Mortality
  • Myelodysplastic syndromes
  • Topotecan

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of low-dose topotecan in myelodysplastic syndromes: A Hoosier Oncology Group (HOG) study'. Together they form a unique fingerprint.

  • Cite this